FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3007628768> ?p ?o ?g. }

• W3007628768 endingPage "4065" @default.
• W3007628768 startingPage "4059" @default.
• W3007628768 abstract "Abstract In a single institution, we have used recombinant interferon- (IFN-) to treat 116 newly diagnosed Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) patients and analyzed the predictive factors for response and survival. The patients whose median age was 50.3 years (range, 9 to 70) were administered IFN- (5 million units/m2/d) subcutaneously. The IFN- dose was subsequently adjusted to maintain the white blood cell and platelet counts between 1.5 and 5 × 109/L, 50 and 100 × 109/L, respectively. At diagnosis, the Sokal score was used to classify the patients into three groups: low (n = 57), intermediate (n = 42), and high risk (n = 16). A complete hematological response (CHR) was achieved in 93 cases (80.2%). Of the 116 patients, 113 were available for cytogenetic evaluation. Fifty patients (43%) achieved a major cytogenetic response (MCR) (=65% marrow Ph− cells), 37 of them having a complete cytogenetic response (CCR). The estimated 5-year survival of the 116 patients was 68% ± 11% (95% confidence interval [CI]) with a median follow-up of 42 months (range, 3 to 114) and 85% ± 11% (95% CI) with a median follow-up of 30.9 (range, 3 to 111) when patients were censored at the time of transplantation. Event-free survival at 5 years (adding death and transplant as event) was 46% ± 11% (95% CI). Using proportional hazards regression to study time-dependent variables, we confirmed that the most significant factor associated with survival was the cytogenetic response (MCR or CCR) (P &lt; .0001). This factor was independent compared with the Sokal score and baseline variables used to calculate the Sokal score. Moreover, using either univariate or multivariate analysis, the achievement of CHR within 3 months was strongly correlated with MCR (P &lt; .0001). Minimum cytogenetic response (mCR, ie, at least 5% of Ph− metaphases) at 3 months was also a significant predictive factor for MCR (P &lt; .0001). These results show that IFN- can induce a high rate of hematological and cytogenetic response when administered in doses leading to myelosuppression. Factors such as the achievement of CHR and mCR within 3 months could be useful to identify early those patients who will not respond to IFN- and who need alternative treatments such as stem cell transplantation." @default.
• W3007628768 created "2020-03-06" @default.
• W3007628768 creator A5001073047 @default.
• W3007628768 creator A5003572390 @default.
• W3007628768 creator A5019150082 @default.
• W3007628768 creator A5027305135 @default.
• W3007628768 creator A5028900948 @default.
• W3007628768 creator A5028925493 @default.
• W3007628768 creator A5031019986 @default.
• W3007628768 creator A5035436135 @default.
• W3007628768 creator A5041817169 @default.
• W3007628768 creator A5044166434 @default.
• W3007628768 creator A5058334809 @default.
• W3007628768 creator A5069539777 @default.
• W3007628768 creator A5087328005 @default.
• W3007628768 date "1998-12-01" @default.
• W3007628768 modified "2023-10-17" @default.
• W3007628768 title "Response at Three Months Is a Good Predictive Factor for Newly Diagnosed Chronic Myeloid Leukemia Patients Treated by Recombinant Interferon-" @default.
• W3007628768 cites W1498708301 @default.
• W3007628768 cites W188630774 @default.
• W3007628768 cites W1928548710 @default.
• W3007628768 cites W2012960044 @default.
• W3007628768 cites W2038990138 @default.
• W3007628768 cites W2039978091 @default.
• W3007628768 cites W2055352087 @default.
• W3007628768 cites W2058190985 @default.
• W3007628768 cites W2076372887 @default.
• W3007628768 cites W2081849198 @default.
• W3007628768 cites W2089483984 @default.
• W3007628768 cites W2094338232 @default.
• W3007628768 cites W2111946771 @default.
• W3007628768 cites W2112085886 @default.
• W3007628768 cites W2127546252 @default.
• W3007628768 cites W2143108209 @default.
• W3007628768 cites W2162258100 @default.
• W3007628768 cites W2337277825 @default.
• W3007628768 cites W2337803710 @default.
• W3007628768 cites W236820854 @default.
• W3007628768 cites W2403285790 @default.
• W3007628768 cites W2438648923 @default.
• W3007628768 cites W2463564403 @default.
• W3007628768 cites W2465903784 @default.
• W3007628768 cites W2508058084 @default.
• W3007628768 cites W2512753555 @default.
• W3007628768 cites W2587781815 @default.
• W3007628768 cites W977069352 @default.
• W3007628768 doi "https://doi.org/10.1182/blood.v92.11.4059" @default.
• W3007628768 hasPublicationYear "1998" @default.
• W3007628768 type Work @default.
• W3007628768 sameAs 3007628768 @default.
• W3007628768 citedByCount "46" @default.
• W3007628768 countsByYear W30076287682012 @default.
• W3007628768 countsByYear W30076287682015 @default.
• W3007628768 countsByYear W30076287682016 @default.
• W3007628768 countsByYear W30076287682017 @default.
• W3007628768 countsByYear W30076287682018 @default.
• W3007628768 countsByYear W30076287682022 @default.
• W3007628768 crossrefType "journal-article" @default.
• W3007628768 hasAuthorship W3007628768A5001073047 @default.
• W3007628768 hasAuthorship W3007628768A5003572390 @default.
• W3007628768 hasAuthorship W3007628768A5019150082 @default.
• W3007628768 hasAuthorship W3007628768A5027305135 @default.
• W3007628768 hasAuthorship W3007628768A5028900948 @default.
• W3007628768 hasAuthorship W3007628768A5028925493 @default.
• W3007628768 hasAuthorship W3007628768A5031019986 @default.
• W3007628768 hasAuthorship W3007628768A5035436135 @default.
• W3007628768 hasAuthorship W3007628768A5041817169 @default.
• W3007628768 hasAuthorship W3007628768A5044166434 @default.
• W3007628768 hasAuthorship W3007628768A5058334809 @default.
• W3007628768 hasAuthorship W3007628768A5069539777 @default.
• W3007628768 hasAuthorship W3007628768A5087328005 @default.
• W3007628768 hasConcept C126322002 @default.
• W3007628768 hasConcept C141071460 @default.
• W3007628768 hasConcept C203014093 @default.
• W3007628768 hasConcept C2778461978 @default.
• W3007628768 hasConcept C2778729363 @default.
• W3007628768 hasConcept C2779282312 @default.
• W3007628768 hasConcept C2911091166 @default.
• W3007628768 hasConcept C44249647 @default.
• W3007628768 hasConcept C50382708 @default.
• W3007628768 hasConcept C71924100 @default.
• W3007628768 hasConcept C90924648 @default.
• W3007628768 hasConceptScore W3007628768C126322002 @default.
• W3007628768 hasConceptScore W3007628768C141071460 @default.
• W3007628768 hasConceptScore W3007628768C203014093 @default.
• W3007628768 hasConceptScore W3007628768C2778461978 @default.
• W3007628768 hasConceptScore W3007628768C2778729363 @default.
• W3007628768 hasConceptScore W3007628768C2779282312 @default.
• W3007628768 hasConceptScore W3007628768C2911091166 @default.
• W3007628768 hasConceptScore W3007628768C44249647 @default.
• W3007628768 hasConceptScore W3007628768C50382708 @default.
• W3007628768 hasConceptScore W3007628768C71924100 @default.
• W3007628768 hasConceptScore W3007628768C90924648 @default.
• W3007628768 hasIssue "11" @default.
• W3007628768 hasLocation W30076287681 @default.
• W3007628768 hasOpenAccess W3007628768 @default.
• W3007628768 hasPrimaryLocation W30076287681 @default.
• W3007628768 hasRelatedWork W1493011226 @default.

• next